Positive News SentimentPositive NewsNASDAQ:DMAC DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis $8.34 +0.14 (+1.76%) As of 03:45 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About DiaMedica Therapeutics Stock (NASDAQ:DMAC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DiaMedica Therapeutics alerts:Sign Up Key Stats Today's Range$8.19▼$8.6050-Day Range$6.32▼$8.3252-Week Range$5.24▼$10.42Volume130,686 shsAverage Volume197,267 shsMarket Capitalization$449.96 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingModerate Buy Company Overview DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases with limited therapeutic options. The company’s research is centered on therapies intended to address neurological and kidney-related conditions. DiaMedica’s lead product candidate is rinvecalin, also known as DM199, a recombinant form of human tissue kallikrein-1. The company is evaluating rinvecalin as a potential treatment for acute ischemic stroke and kidney diseases, including conditions involving impaired renal function. The therapy is designed to activate the kallikrein-kinin system, which may help support blood flow and protect tissue. DiaMedica is headquartered in Minneapolis, Minnesota, and conducts its development activities through clinical research programs and collaborations with medical institutions and research organizations. Rick Pauls serves as the company’s president and chief executive officer. As a clinical-stage biotechnology company, DiaMedica has not yet established a broad commercial product portfolio.AI Generated. May Contain Errors. Read More DiaMedica Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreDMAC MarketRank™: DiaMedica Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 661st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingDiaMedica Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDiaMedica Therapeutics has a consensus price target of $12.00, representing about 41.3% upside from its current price of $8.49.Amount of Analyst CoverageDiaMedica Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about DiaMedica Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for DiaMedica Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DiaMedica Therapeutics is -11.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DiaMedica Therapeutics is -11.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiaMedica Therapeutics has a P/B Ratio of 7.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DiaMedica Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.71% of the float of DiaMedica Therapeutics has been sold short.Short Interest Ratio / Days to CoverDiaMedica Therapeutics has a short interest ratio ("days to cover") of 36.67, which indicates bearish sentiment.Change versus previous monthShort interest in DiaMedica Therapeutics has recently increased by 1.72%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDiaMedica Therapeutics does not currently pay a dividend.Dividend GrowthDiaMedica Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment1.79 News SentimentDiaMedica Therapeutics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for DiaMedica Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for DMAC on MarketBeat in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.00% of the stock of DiaMedica Therapeutics is held by insiders.Percentage Held by Institutions10.12% of the stock of DiaMedica Therapeutics is held by institutions.Read more about DiaMedica Therapeutics' insider trading history. Receive DMAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DMAC Stock News HeadlinesDiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR ResultsSeptember 30 at 9:00 AM | businesswire.comDiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 20, 2026 | americanbankingnews.comTrump Wants to Reprice America's Gold at Market ValueThe US government still values its gold reserves at 42 dollars an ounce, a price Congress set in 1973. Gold trades above 4000 today, leaving official books showing about 11 billion dollars for holdings worth more than 1 trillion in the real market. A bill now moving through Congress would require the Treasury to reprice that gold at current market value, while companion legislation could trigger the first audit of US gold holdings in more than 65 years. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free.September 30 at 1:00 AM | Concord Gold Capital (Ad)DiaMedica Therapeutics to Participate in Upcoming September Investor ConferencesSeptember 2, 2026 | finance.yahoo.comDiaMedica (DMAC) Q2 2026 Earnings Call TranscriptAugust 18, 2026 | finance.yahoo.comDiaMedica Therapeutics Inc. (DMAC) Q2 FY2026 earnings call transcriptAugust 12, 2026 | finance.yahoo.comDiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...August 11, 2026 | finance.yahoo.comDiaMedica anticipates ReMEDy2 interim analysis in Q1 2027 as enrollment surpasses 85% of 200-patient triggerAugust 11, 2026 | seekingalpha.comSee More Headlines DMAC Stock Analysis - Frequently Asked Questions How have DMAC shares performed this year? DiaMedica Therapeutics' stock was trading at $7.96 on January 1st, 2026. Since then, DMAC stock has increased by 6.7% and is now trading at $8.49. How were DiaMedica Therapeutics' earnings last quarter? DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) released its quarterly earnings data on Monday, August, 10th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.01. Read the conference call transcript. When did DiaMedica Therapeutics IPO? DiaMedica Therapeutics (DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO. How do I buy shares of DiaMedica Therapeutics? Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DiaMedica Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that DiaMedica Therapeutics investors own include NVIDIA (NVDA), ADMA Biologics (ADMA), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX), Ardelyx (ARDX) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/10/2026Today9/30/2026KOL event10/23/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, DMAC's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DMAC CIK1401040 Webwww.diamedica.com Phone(763) 496-5454FaxN/AEmployees35Year Founded2000Price Target and Rating Average Price Target for DiaMedica Therapeutics$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+43.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$32.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-77.76% Return on Assets-69.43% Debt Debt-to-Equity RatioN/A Current Ratio6.72 Quick Ratio6.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book7.77Miscellaneous Outstanding Shares53,926,000Free Float51,230,000Market Cap$452.44 million OptionableOptionable Beta0.98 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:DMAC) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredLegendary U.S. Congressman Issues WarningDr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dol...Altimetry | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
